21 August 2018
Visiongain’s new report Global Biosimilars and Follow-On Biologics Market 2017-2027: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones indicates that the global biosimilars and follow-on biologics market will see $21.6bn in spending in 2021.
The global biosimilars and follow-on biologics market is expected to grow at a CAGR of 38.8% in the first half of the forecast period and CAGR of 11.3% in the second half of the forecast period. The market is estimated at $5.31bn in 2016 and $41.07bn in 2027.
The lead analyst of the report said: “In 2016, three sectors - biosimilar EPO, biosimilar insulin, biosimilar monoclonal antibodies, and biosimilar growth hormones - accounted for more 60.6% of market revenues. The first two of these sectors will record strong growth throughout the next ten years. Growth will be restrained in the biosimilar growth hormones submarket by steady uptake for branded therapies, high brand loyalty, as well as the launch of long-acting growth hormones. Rising diabetes incidence will drive demand for biosimilar human insulin in emerging markets, while the launch of biosimilar insulin glargine in developed markets during the forecast period will drive growth in the biosimilar insulin analogues sector.
Biosimilar mAbs (monoclonal antibodies) will be the fastest growing sector of the biosimilars market between 2016 and 2027, with a high 12-year CAGR of 31.6%, with revenues growing from just $1.056bn in 2016 to $9.8bn in 2027.”
The 318-page report contains 128 tables and 68 figures that add visual analysis in order to explain the developing trends within the Global Biosimilars and Follow-on Biologics Market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the leading segments of this market: Monoclonal antibodies (mAbs), Fusion proteins, Insulin, Erythropoietin (EPO), Granulocyte colony-stimulating factor (G-CSF), Interferons, Growth hormones and Fertility hormones.
This report also provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for these submarkets: Rituximab, infliximab, trastuzumab, adalimumab, bevacizumab, human insulin, insulin analogues, insulin glargine, insulin lispro, Interferon alfa, interferon beta and Etanercept.
The 318-page report offers market forecasts for the US, Japan, Germany, France, UK, Italy, Spain, China, India, South Korea, Russia and Brazil.
The report Global Biosimilars and Follow-On Biologics Market 2017-2027: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones report will be of value to anyone who wants to better understand the biosimilars and follow-on biologics market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the biosimilars and follow-on biologics industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
There is an increasing focus to identify diseases that currently do not have a vaccine.
20 June 2019
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.